Analysts have clear opinions on PHR.
There are 4 analysts on the Wall offering 12 month price targets for Phreesia in the last 3 months. The average price target is $32.67 with a high forecast of $33.00 and a low forecast of $32.00. The average price target represents a 25.65% increase from the last price of $26.00.
Phreesia, Inc. (PHR) is followed by 4 analysts on the street.
Steven Halper from Cantor Fitzgerald rates it a Buy with a target of $32.00.
Similarly, Last month John Ransom of Raymond James Initiated a Buy with a target of $33.00.
The consensus on the street is Strong Buy.
What does Phreesia, Inc.(PHR) do ?
Phreesia, Inc. provides patient check-in solutions for medical practices. It provides solutions that transform the healthcare experience by engaging patients in their care and enabling healthcare provider organizations to optimize operational efficiency, improve profitability and enhance clinical care. Through the SaaS-based Phreesia Platform the company offers healthcare provider organizations a robust suite of solutions to manage the patient intake process and a payments solution for secure processing of patient payments. Its platform also provides life sciences companies with an engagement channel for targeted and direct communication with patients. Phreesia was founded by Chaim Indig and Evan Roberts in January 2005 and is headquartered in New York, NY.
Phreesia, Inc. (PHR) Insider Trades
Multiple company employees have indulged in significant insider trading. Phreesia, Inc. disclosed the following in a document filed with the US Securities and Exchange Commission (SEC):
10%, Polaris Venture Management Co. V, L.L.C. : S – Sale(-$8,741,965) of PHR in the trading session of 2019-12-17.
Dir Perricelli Scott : S – Sale(-$48,958,000) of PHR in the trading session of 2019-12-17.
10% Llr Capital Iv, LLC : S – Sale(-$48,958,000) of Phreesia, Inc. in the trading session of 2019-12-17.